🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Contributor sign in
Latest
Clinical Trials in Turkey / NCT01878669
Active, not recruiting Phase 3

Effects of N-acetyl Cysteine During Percutaneous Coronary Intervention

NCT01878669 · tracked via the Priya Life Science Turkey tracker
Phase
Phase 3
Started
2013-01
Last updated
2025-05-20

Condition(s) studied

Coronary Artery Disease

Investigational drug(s) / intervention(s)

N-acetyl cysteine →Saline

Study summary

The aim of this study is to evaluate the effects of N-acetyl cysteine on periprocedural myocardial infarction and major cardiac and cerebral events in patients undergoing percutaneous coronary intervention and who have moderate to high risk for contrast induced nephropathy.

Eligibility

Sex
ALL
Min age
18 Years
Max age
85 Years
Healthy volunteers
No
Inclusion Criteria: * Patients \> 18 years old undergoing percutaneous coronary intervention and who have moderate to high risk for contrast induced nephropathy (Mehran Score ≥ 5) Exclusion Criteria: * Primary percutaneous coronary intervention * Low risk for contrast induced nephropathy (Mehran Score \< 5) * Use of nephrotoxic agents (NSAIDs, aminoglycosides,recent contrast injection...) * Infection * Pregnancy, Lactation * Renal failure requiring dialysis * Hepatic failure * History allergy for NAC * History of Asthma * Chronic nitrate usage * Malignancy * Use of corticosteroids * Leukocytosis,Thrombocytosis,Anemia * Blood pressure of \>180/100mmHg despite anti-hypertensive therapy

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
Suleyman Demirel University Isparta Mediterranean Region

More Suleyman Demirel University trials in Turkey

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT01878669 on ClinicalTrials.gov ↗ ← All trials in Turkey